Partners
Tampere University (TAU) is one of the most multidisciplinary universities in Finland. They bring together research and education in technology, health and society. The University is known for its excellence in teaching and research and it collaborates with hundreds of universities and organisations worldwide. Their community consists of about 22,500 students and around 4,200 staff members from more than 80 countries. The Faculty of Medicine and Health Technology (MET) focuses on combining clinical medicine, life sciences, and biomedical engineering, housing over 300 researchers. The Eye Regeneration group, led by Professor Skottman, develops stem cell-based tools for corneal and retinal repair, leveraging 3D bioprinting technologies.
ASPHALION is a key player in the global healthcare sector and a reference in implementing new regulatory standards. Its experts have provided solutions to over 1,000 Pharmaceutical, Biotech, and MedTech companies from 50+ countries in 5,000+ projects, covering non-clinical and clinical development, CMC, dossier writing, regulatory procedures, vigilance, eSubmissions, and data management. It offers strategic advice, expert consulting, operational support, and full outsourcing for all therapeutic areas. To ensure the best solutions, ASPHALION collaborates with international authorities, notified bodies, scientific associations, and key opinion leaders, maintaining a strong network of geographic and functional partners.
AM Technologies by Binter is shaping the future with Advanced Additive Manufacturing Technologies. Their approach involves developing, patenting, manufacturing, commercialising and licensing, to unlock the potential of the Additive Manufacturing industry. Their team is composed of passionate visionary entrepreneurs and the world’s leading engineers and scientists, supported by a global partner network, the EU, and Business Finland.
Cellbox Solutions develops innovative logistics solutions for the global BioMed industry. Its flagship product, the Cellbox™ is a robust, portable incubator with active CO₂ and temperature control, ensuring the safe transport of living cells and biological samples under optimal laboratory conditions. Today, Cellbox Solutions collaborates closely with more than 150 customers to tackle diverse cell transport challenges and continuously improve its products. The development and assembly of Cellbox™ incubators were carried out in partnership with Fraunhofer EMB and is now supported by a European EIC grant.
Crowdhelix is an Open Innovation platform that forges links between an international network of excellent researchers and innovating companies so that they can plan and deliver pioneering collaborative projects. Through the application of AI technology, they connect businesses, universities, and research centres to develop their ideas into funding proposals and deliver cutting-edge projects. Collectively their network has secured €11.79 billion of project funding, with Crowdhelix consistently identified as delivering strategic value across a wide variety of business cases.
The University of Helsinki, founded in 1640, is an international community of over 40,000 students and employees, which uses the power of science to create a sustainable future for the benefit of the entire world. It is ranked among the top one percent of universities in the world. The multidisciplinary university operates on four campuses in Helsinki and at the university centres in Lahti, Mikkeli and Seinäjoki. It also has six research stations in different parts of Finland and one in Kenya.
The Department of Ophthalmology at the University of Cologne is a leading German research institution. It excels in diagnosing and treating all eye diseases, offering top-tier conservative and surgical therapies. Key corneal specialities include anti-angiogenic therapy, lamellar corneal surgery, specialised laser treatments, corneal prosthetics, and surface reconstruction. The centre is committed to preserving and restoring vision through excellence in medicine, research, and patient care.
StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness. They are the pioneers of combining iPS-derived cells with functional biomaterials. Their primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery. The team at StemSight is comprised of top scientists in regenerative medicine and tissue engineering for eye applications.
The MERLN Institute for Technology-Inspired Regenerative Medicine at Maastricht University strives to maintain a leading position in the field of biomedical engineering by combining creative research with training a generation of interdisciplinary scientists. MERLN’s activities operate at the interface of biology, engineering and medicine to maximise impact at the level of public involvement and the commercialisation of research.